Hope and Challenges in the Quest for an HIV Cure
For over four decades, researchers have been pursuing a solution to the elusive HIV virus, which is notorious for its rapid mutations and ability to lurk in long-lived reservoirs within the body. The presence of these reservoirs is a significant barrier to finding a permanent cure. While speculation exists that economic interests might impede the discovery of a cure, advancements in prevention science have accelerated, offering hope through innovative treatments. Drugs like lenacapavir, which can be administered biannually, are hailed as significant strides in prevention, yet many individuals living with HIV continue to ask the pressing question: when will a cure be found?
A recent discussion hosted by the Global Network of People Living with HIV (GNP+) delved into HIV cure research, particularly focusing on pediatrics, ethical considerations, and the role of the hashtag #PLHIV in fostering community trust and guiding research priorities. Dr. Gabriela Cromhout, along with advocate Nomonde Ngema, highlighted the realities and ethical aspects of conducting cure research for children, emphasizing the invaluable contribution of individuals living with HIV in shaping research agendas.
Dr. Cromhout leads the Ucwaningo Lwabantwana cohort in KwaZulu-Natal, a study that translates to “learning from children” in isiZulu. This initiative monitors mothers and their newborns who contracted HIV in utero, enrolling children from birth and following them throughout their early lives. The oldest participants are now approaching their eleventh birthdays. Dr. Cromhout elaborates, “The primary objective is to determine whether early treatment can pave the way for a cure.”
However, the term “cure” in HIV research is a complex one. Within adult studies, scientists differentiate between a “true cure,” which implies total eradication of the virus, and more attainable goals like sustained remission without the reliance on antiretroviral therapy (ART). In essence, remission means the virus is controlled by the immune system without requiring daily medication.
“In pediatric research, we primarily seek ART-free remission,” Dr. Cromhout explains. It’s not about complete eradication but achieving control over the virus without continuous treatment. For families raising children with HIV, this distinction is crucial. While modern ART allows these children to lead healthy lives and attend school, the need for lifelong adherence often poses challenges, especially as children grow into teenagers.
Despite the advancements, the burden of daily medication remains. Crombute shares, “While treatment is remarkable, the requirement to remember to take it every day, coupled with access challenges, is still a significant burden. Reducing that burden is a universal goal.”
The foundation of pediatric cure research sits on a unique paradox: children’s biological differences from adults may present novel opportunities for treatment. Historically, untreated infants progressed to severe disease more rapidly than adults. Yet, with treatment initiation shortly after birth—sometimes within days—children’s adaptable immune systems might be able to limit the viral reservoir and make remission a realistic goal. This strategy is central to the Ucwaningo Lwabantwana cohort, where researchers aim to understand if early treatment can mitigate the reservoir’s size, creating conditions for a future where monitored treatment cessation might lead to sustained control.
However, pediatric cure research extends beyond biology. Engaging with children introduces ethical and social complexities absent from adult studies. In South Africa, individuals under 18 are unable to provide full consent for research participation; parental or guardian consent is essential, alongside age-appropriate assent from children aged seven and older. Disclosing a child’s HIV status is also a sensitive topic, and many young patients learn of their diagnosis only later in childhood.
“We’re not only working with a child, but with an entire family unit,” says Dr. Cromhout. The dynamics within families—grandparents, parents, and siblings—play a pivotal role in whether a child adheres to treatment and participates in research, underscoring the need for research approaches that are culturally sensitive and family-friendly.
Ngema, an advocate born with HIV, relates the importance of these discussions on a personal level. “When I was a child and came to grips with my status, I wanted to know: will there ever be a cure?” she recalls, highlighting the stark difference in responses over the years. Initially skeptical of cure-related meetings, she found herself inspired by scientists presenting ongoing research realities, rather than promises of miraculous solutions.
The conversation around cures must remain rooted in honesty, Ngema insists. Terms like “breakthrough” can inadvertently raise unrealistic expectations among those living with HIV. She emphasizes the importance of consistent language—uttering “HIV cure research” to reflect its ongoing and uncertain nature. “Hope is essential,” she concludes. “But honesty is paramount.”
Meanwhile, broader skepticism regarding the pharmaceutical industry persists, as some communities suspect that cures are withheld for profit motives tied to lifelong ART. Dr. Cromhout challenges this narrative, explaining that HIV cure research is fraught with scientific complexity and high costs. Unlike standard treatments that suppress viral replication, a true cure involves eradicating or permanently silencing every viral reservoir cell, a daunting task given the virus’s ability to mutate.
Prevention research has, meanwhile, made impressive strides. Long-acting injectables like lenacapavir—celebrated for their ability to ease the treatment burden—serve only as preventive measures and do not address the needs of millions already living with HIV. Dr. Cromhout notes, “Prevention and cure research are parallel efforts rather than competing agendas; both are essential in addressing this health crisis.”
As the Ucwaningo Lwabantwana cohort’s children enter adolescence, new questions arise about their participation in research, the significance of disclosure, and whether early treatment leads to measurable remission outcomes in the future. The study continues its work—collecting valuable data and fostering trust in a global battle against HIV, even if progress remains slow.
Ngema reflects, saying, “At one time, pediatric treatment was a grey area. Now, children are actively included in cure conversations, which fills me with hope.” While a cure remains elusive, HIV’s relentless nature persists, and the debate around treatment and prevention continues, accompanied by a collective call for clarity, ethics, and trust in this ongoing journey.
— Reported by Nexio News
